[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dexiong Han\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100632607","efficacy-of-electroacupuncture-for-acute-herpes-zoster-associated-pain-and-biomarker-evaluation-100632607",false,"NCT07515885","Efficacy of Electroacupuncture for Acute Herpes Zoster-Associated Pain and Biomarker Evaluation","Research on the Therapeutic Effect of Electroacupuncture on Acute Herpes Zoster-Associated Pain and Its Anti-inflammatory Injury Mechanism","Inclusion Criteria:\n\n1. Patients who meet the diagnostic criteria for acute HZ27 and skin symptom appears less than 7 days;\n2. Only have lesions in the trunk and limbs;\n\n2\\. Patients with a Numerical Rating Scale (NRS) score ≥ 4; 3. Aged between 20 and 80 years; 4. Patients voluntarily participate in the trial and are willing to sign the informed consent.\n\nExclusion Criteria:\n\n1. Special types of HZ that occur in head, eyes, viscera, etc. or those combined with other skin diseases;\n2. Has received relevant treatment and it may affect the observation indicators;\n3. Pregnant and lactating women;\n4. Patients who are allergic to iodophor or other topical disinfectants, or a history of sudden, potentially life-threatening systemic allergic reactions;\n5. Those who are afraid of acupuncture or have metal implants and are not suitable for EA treatment;\n6. Those with contraindications to pregabalin such as congestive heart disease and heart failure;\n7. Patients with severe primary diseases such as liver, kidney, cardiovascular and cerebrovascular, metabolic, autoimmune system diseases, malignant tumors, etc., and those with mental illness;\n8. Patients who have hematologic diseases or coagulation disorders;\n9. Patients who are currently participating in other clinical studies.","ALL","20 Years","80 Years",{"count":20,"type":21},228,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background: Herpes zoster (HZ) is an acute dermatological condition caused by the varicella-zoster virus. Its onset is characterized by severe pain, imposing significant physical and psychological burdens on patients. Acupuncture offers distinct advantages in treating acute herpes zoster and associated pain. However, the therapeutic efficacy of electroacupuncture for acute herpes zoster, its potential to reduce PHN incidence, and the role of biomarkers in predicting PHN incidence require further clinical validation.\n\nMethods: A total of 228 patients with acute herpes zoster will be recruited from 3 hospitals and randomly assigned to EA group or medication-alone group or sham acupuncture group in a 1:1:1 ratio, utilizing multicenter stratified block randomization. The trial will involve a 2 week treatment period, and a 3-month follow-up period. All variables will be evaluated at week 0, week 1, week 2, and on the 90th day after rash onset. All participants will continue antiviral medication treatment. Primary outcome is Numerical Rating Scale; secondary outcomes include herpes lesion crusting time, pain episodes within a 24-hour period, Hamilton Anxiety Scale, Hamilton Depression Scale, 36-Item Short Form Health Survey, changes of biomarkers (Erythrocyte sedimentation rate, C-reactive protein, Tumor Necrosis Factor-α, Interleukin-10, Substance P and neuropeptide Y) and PHN incidence rate. All adverse effects will be assessed during the trial.\n\nConclusion: This study will elucidate the efficacy of electroacupuncture in treating acute herpes zoster, whether electroacupuncture can reduce the incidence of PHN, and the role of biomarkers in predicting the incidence of PHN.",[27],"Acute Herpes Zoster","RECRUITING","2026-06-11",{"date":31,"type":32},"2026-06-16","ACTUAL",{"date":34,"type":32},"2025-09-01",{"date":36,"type":21},"2028-12-31",{"name":38,"class":39},"Dexiong Han","OTHER_GOV",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100592240","electroacupuncture-for-phn-efficacy-and-biomarker-evaluation-in-a-multicenter-randomized-sham-controlled-trial-protocol-100592240","NCT06990854","Electroacupuncture for PHN: Efficacy and Biomarker Evaluation in a Multicenter, Randomized, Sham-Controlled Trial Protocol","Inclusion Criteria:\n\n* Meet the diagnostic criteria for PHN;\n* Age between 20 and 80 years old;\n* Voluntarily participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Presence of severe liver or kidney dysfunction, malignant tumors, or other serious diseases;\n* Presence of hematologic diseases or coagulation disorders;\n* Presence of mental illness or other cognitive impairments, unable to understand or unwilling to cooperate with the study requirements.",{"count":48,"type":21},207,[24],"The investigators are conducting a clinical study with the following objectives: to evaluate the clinical efficacy of electroacupuncture combined with pregabalin in treating Postherpetic Neuralgia(PHN); to investigate the correlation between serum biomarker levels and pain symptoms;and to determine whether serum biomarkers can serve as prognostic indicators for PHN.\n\nThis study utilizes a randomized controlled trial design with assessor blinding. A total of 207 eligible PHN patients were randomly assigned to three groups in a 1:1:1 ratio: the electroacupuncture group, the pharmacotherapy group, and the sham acupuncture group. Comparative analyses of pain intensity and serum biomarker concentrations were conducted across these groups.\n\nFor the assessment of clinical outcomes, the investigators employed the following measures: the Numerical Rating Scale(NRS), the Hamilton Anxiety Scale(HAMA), the Hamilton Depression Scale(HAMD), the 36-Item Short Form Health Survey(SF-36), serum levels of substance P(SP)and Neuropeptide Y(NPY), and inflammatory markers(IL-10,TNF-α). These assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment.\n\nThe investigators anticipate that this clinical trial will enhance our understanding of the therapeutic efficacy and underlying mechanisms of acupuncture in managing PHN. It aims to elucidate the relationship between serum biomarkers and the clinical manifestations of PHN, as well as to explore their potential prognostic value in disease outcomes.",[52],"Postherpetic Neuralgia ( PHN )",[54,55,56,57,58],"acupuncture","Postherpetic Neuralgia","serum biomarkers","serum substance P","Neuropeptide Y","NOT_YET_RECRUITING","2025-07-02",{"date":62,"type":32},"2025-07-09",{"date":64,"type":21},"2025-07-01",{"date":66,"type":21},"2026-12",{"name":38,"class":39},""]